BioNTech (BNTX) LONG — 4H ALMA Setup (WR 80%)█ SETUP
NASDAQ:BNTX · 4H · long only.
(Context: BioNTech — mRNA platform; oncology pivot post-COVID; Pfizer Comirnaty partner.)
ALMA Averaging Strategy: ALMA 3 / σ2, SD band 2, min diff 6/1, 25% per bar, up to 4 adds, hard stop −10% from average entry.
Strategy Tester (BNTX 4H):
Win rate 80% · profit factor 2.3 · max drawdown 17%
Avg winning trade +10.6% · avg losing trade −8.8%
Typical hold ~18×4H bars on winners — biotech mean-reversion sleeve on the US cash grid
█ WHY NOW
Monday US cash open — fresh 4H ALMA long on 13 Jul 13:30 UTC ~ $91.42 .
First lot on the template at the VWAP support cluster (~$91.02–91.36) after a July grind in the low-$90s — bar-close on the 4H sleeve, not an oncology-headline or patent-win chase.
Hard stop zone −10% from fill ~ $82.28 . Exits follow Pine ALMA flip + min diff or the hard stop.
═
█ MACRO
Sector: BNTX = mRNA / immuno-oncology pivot — COVID revenue fade, pipeline catalysts (pumitamig, BNT324 prostate ADC Phase 3), ~€16.8B cash (Q1).
Tape (Jun–13 Jul): Mixed window — UPC patent win vs Promosome (02–08 Jul, Comirnaty cleared in Europe) and Lancet mRNA efficacy meta-analysis vs German manufacturing divestiture talks (~1,860 jobs, Handelsblatt/Reuters 03 Jul). $1B ADS buyback active (~$99M repurchased mid-June, avg ~$88.6). Morgan Stanley Buy maintained, PT $126→$119 (08 Jul); Morningstar 2-star «overvalued» after ~+11% over 30 days on one tape slice. Next: Q2 earnings ~04 Aug 2026 ; H2 oncology readouts on the calendar.
Execution is 4H ALMA at ~$91.42 in the support band — not a post-rally chase into MS’s trimmed PT zone (~$115–119).
█ OUTLOOK
Positive factors
- 80% WR · PF 2.3 · avg win +10.6% vs avg loss −8.8% on 109×4H trades — workable skew for a volatile biotech name
- Fresh 4H entry inside the 24h publish window — first lot at US cash, not a scale-in add
- ALMA — execution TF aligned: 4H LONG · L:1 vs avg L:3.8 — template direction matches the bar
- VWAP — support at fill: active support ~$91.02 / ~$91.36 · chart touch Support — entry sits on the lower VWAP band, not mid-range
- SMC — demand at fill: 4H bull FVG raid ~$91.42 (10 Jul) · 1D bull FVG enter ~$91.49 + OB enter normal bull — same-session demand tags
- EMA — below-session stretch (fuel): 1H Cur S:14 vs Avg S:4.2 · +0.8% dev — entry ladder stretched below on the faster TF
- Macro tailwinds in-window: UPC win + buyback execution vs restructuring noise — mixed tape suits a mean-reversion sleeve, not a breakout call
Negative factors
- ALMA — slow-TF headwind: 1D SHORT · S:5 vs avg S:4.2 · OVERHEAT-S — daily band still short-biased; adds risky if price extends without reset
- EMA — bear stack: 4H / 1D / 3D / 1W all Below — no full MTF reclaim; 4H only S:3 (+0.6% dev), not a deep crash discount
- VWAP — overhead: resistance ~$94.45 / ~$94.17 (Jul) — first mean-reversion ceiling a few percent above fill
- Restructuring headline risk: German site sales, job cuts, JPT Peptide exit — gap risk on US opens
- Analyst caution: MS PT cut · Morningstar overvalued — sentiment not uniformly bullish despite patent win
- Earnings ~04 Aug — binary biotech window ahead; 4H sleeve can whipsaw into the print
- Single first lot — no averaged discount yet if the bar extends lower before adds qualify
- Promosome may appeal UPC ruling — residual legal overhang
Takeaway: the 80% 4H template, VWAP support cluster, bull FVG/OB tags at ~$91, and 1H below-EMA stretch support a disciplined mean-reversion long at the cash open — but 1D ALMA OVERHEAT-SHORT and the full EMA bear stack cap conviction; macro is patent/buyback positive vs restructuring/analyst downgrade negative — biotech grind in the low-$90s, not a clean oncology breakout; nominal risk stays on −10% / Pine exit.
Base case: 4H ALMA holds ~$89–94 · VWAP support absorbs dips · slow work toward ~$94–95 resistance if bull FVG shelf holds.
Bear case: lose 4H ALMA · restructuring headline accelerates · pre-earnings de-risking · flush toward hard stop ~$82.28 from ~$91.42 entry.
Chart: BATS:BNTX 4H — ALMA Averaging Strategy.
Educational idea. Live position — past backtest ≠ future results. NFA.
Long
